10779/rcsi.10765331.v1
Emily J. Ryan
Emily J.
Ryan
Alan J. Ryan
Alan J.
Ryan
Arlyng Gonzalez Vazquez
Arlyng Gonzalez
Vazquez
Anahà Philippart
AnahÃ
Philippart
Francesca E. Ciraldo
Francesca E.
Ciraldo
Christopher Hobbs
Christopher
Hobbs
Valeria Nicolosi
Valeria
Nicolosi
Aldo R. Boccaccini
Aldo R.
Boccaccini
Cathal Kearney
Cathal
Kearney
Fergal J. O'Brien
Fergal J.
O'Brien
Collagen scaffolds functionalised with copper-eluting bioactive glass reduce infection and enhance osteogenesis and angiogenesis both in vitro and in vivo.
Royal College of Surgeons in Ireland
2019
Osteomyelitis
Copper
Bioactive glass
Antibacterial
Osteogenesis
Angiogenesis.
Anatomy
2019-11-23 11:40:19
Journal contribution
https://repository.rcsi.com/articles/journal_contribution/Collagen_scaffolds_functionalised_with_copper-eluting_bioactive_glass_reduce_infection_and_enhance_osteogenesis_and_angiogenesis_both_in_vitro_and_in_vivo_/10765331
<p>The bone infection osteomyelitis (typically by Staphylococcus aureus) usually requires a multistep procedure of surgical debridement, long-term systemic high-dose antibiotics, and - for larger defects - bone grafting. This, combined with the alarming rise in antibiotic resistance, necessitates development of alternative approaches. Herein, we describe a one-step treatment for osteomyelitis that combines local, controlled release of non-antibiotic antibacterials with a regenerative collagen-based scaffold. To maximise efficacy, we utilised bioactive glass, an established osteoconductive material with immense capacity for bone repair, as a delivery platform for copper ions (proven antibacterial, angiogenic, and osteogenic properties). Multifunctional collagen-copper-doped bioactive glass scaffolds (CuBG-CS) were fabricated with favourable microarchitectural and mechanical properties (up to 1.9-fold increase in compressive modulus over CS) within the ideal range for bone tissue engineering. Scaffolds demonstrated antibacterial activity against Staphylococcus aureus (up to 66% inhibition) whilst also enhancing osteogenesis (up to 3.6-fold increase in calcium deposition) and angiogenesis in vitro. Most significantly, when assessed in a chick embryo in vivo model, CuBG-CS not only demonstrated biocompatibility, but also a significant angiogenic and osteogenic response, consistent with in vitro studies. Collectively, these results indicate that the CuBG-CS developed here show potential as a one-step osteomyelitis treatment: reducing infection, whilst enhancing bone healing.</p>